Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo offers hope for tough lung cancer

NCT ID NCT06295432

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, DZD9008 and AZD4205, together in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard treatments. About 90 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial People'S Hospital

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    COMPLETED

    Xi'an, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    COMPLETED

    Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.